OTCM
PBIO
Market cap28kUSD
Jul 09, Last price
0.00USD
Jan 2017
-99.99%
Name
Pressure Biosciences Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Pressure BioSciences, Inc. develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide. The company’s products/services are based on Ultra Shear Technology platform, which turns hydrophobic oil-based supplements, therapeutics, and other active ingredients to water-soluble, bioavailable, oil-in-water nano emulsion formulations; BaroFold Technology platform, that is used to improve the quality and lower the production costs of protein biotherapeutics; and Pressure Cycling Technology platform which uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to control bio-molecular interactions in sample preparation. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB440, Barocycler HUB880, and the Shredder SG3; Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, and PCT-Micro Pestle; UltraShear Mini, UltraShear K45, and UltraShear Max; and application specific kits, as well as consumable products. The company also provides pain relief, skincare solutions, personal wellness, athletic recovery, and specialized pet care products. It serves researchers at academic laboratories, government agencies, biotechnology and pharmaceutical companies, other life science institutions, and food/beverages laboratories. The company has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. Pressure BioSciences, Inc. was incorporated in 1978 and is headquartered in Canton, Massachusetts.
IPO date
Oct 31, 1996
Employees
16
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||